

Part I: Basis of the Disease

Section A: Genetics and epigenetics

1. Major histocompatibility complex and SLE
2. Lupus Susceptibility genes
3. Epigenetics in systemic lupus erythematosus and the integration of molecular pathways

Section B: Immunopathogenesis

4. Autoantigens, antigenic mimicry, and immune complexes
5. B-cell Biology, tolerance and autoantibodies
6. T-Cell Biology, tolerance and regulation
7. Polymorphonuclear cells
8. Metabolic and mitochondrial dysfunction in SLE
9. Immunopathogenesis: the role of mucosal and skin microbiota in SLE

Section C: Disease effectors and modifiers

10. Complement and SLE
11. Interferons and cytokines in SLE pathogenesis and therapy
12. Innate immunity in SLE pathogenesis
13. Sex bias in SLE

Section D: Tissue injury-the Biology

14. Mechanisms of tissue injury in lupus nephritis
15. The skin
16. The brain in SLE: mechanisms and detection of injury and therapeutic strategies
17. The role of infections in SLE pathogenesis
18. Tissue injurythe biology: SLE-associated vascular disease and antiphospholipid syndrome

Part II: Clinical presentation of disease

Section A: Clinical presentation

19. Epidemiology of SLE and related diseases: incidence, prevalence, and mortality
20. The clinical presentation of systemic lupus erythematosus and laboratory diagnosis
21. Passively acquired lupus in the fetus and neonate
22. Systemic lupus erythematosus in children
23. Environmental and drug-induced lupus
24. Reproductive health

25. Monitoring disease activity

26. Overlap syndromes

Section B: Specific organ involvement and clinical presentation

27. Nervous system

28. Skin

29. Kidney disease

30. Cardiovascular disease in lupus

31. Pulmonary manifestations of systemic lupus erythematosus

32. GI hepatic and nonhepatic diseases

33. Musculoskeletal system: articular disease, myositis, and bone metabolism

34. Clinical presentation of antiphospholipid syndrome

35. Hematology: cytopenias

36. Malignancy risk and screening

Section C: Treatment of systemic lupus erythematosus

37. Antimalarial drugs (and lupus)

38. Glucocorticoids

39. Immunosuppressive therapy in SLE

40. Pipeline therapies and future drug development

41. Challenges of systemic lupus clinical trials